| Recruiting | Spatially Fractionated Radiation Treatment for Gynaecological Cancers NCT06644846 | Tata Memorial Hospital | N/A |
| Withdrawn | A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors NCT06372574 | Genentech, Inc. | Phase 1 |
| Recruiting | Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer NCT06208657 | Australian & New Zealand Children's Haematology/Oncology Group | Phase 1 / Phase 2 |
| Not Yet Recruiting | Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors NCT04889742 | Charite University, Berlin, Germany | Phase 2 |
| Recruiting | Personalized Neoantigen Peptide Vaccines for Solid Tumors NCT07002203 | Seqker Biosciences, Inc. | Phase 1 / Phase 2 |
| Unknown | Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer NCT06103617 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Completed | Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractor NCT05990920 | NKGen Biotech, Inc. | Phase 1 |
| Recruiting | IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors NCT05958121 | Immatics Biotechnologies GmbH | Phase 1 / Phase 2 |
| Recruiting | PREventing Second Cancers With DOSTARlimab NCT05855811 | Centre Leon Berard | Phase 2 |
| Unknown | Feasibility Study of Lidocaine Infusion During Bowel Cancer Surgery for Cancer Outcome NCT05250791 | Imperial College London | N/A |
| Unknown | Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma NCT05626829 | Jian Guan | Phase 2 |
| Completed | A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors NCT05396300 | Weijia Fang, MD | Phase 1 |
| Active Not Recruiting | IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor NCT05359445 | Immatics Biotechnologies GmbH | Phase 1 |
| Completed | Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endo NCT05364905 | ARCAGY/ GINECO GROUP | — |
| Recruiting | Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors NCT05189054 | Peking University Third Hospital | — |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Ca NCT05043922 | Haihe Biopharma Co., Ltd. | Phase 2 |
| Unknown | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors NCT05415475 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Completed | Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions NCT05045040 | Yosuke Uchitomi | N/A |
| Completed | Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients NCT05002140 | XRad Therapeutics Inc | Phase 1 |
| Withdrawn | Nanoparticles and Hypofractionated Protontherapy for Reirradiation of Pantumor Relapse NCT04784221 | Centre Francois Baclesse | Phase 2 |
| Completed | Recurrence After Whipple's (RAW) Study NCT04596865 | University Hospital Plymouth NHS Trust | — |
| Recruiting | Cabozantinib to Treat Recurrent Liver Cancer Post Transplant NCT04204850 | University Health Network, Toronto | Phase 2 |
| Recruiting | Pembrolizumab, Ibrutinib and Rituximab in PCNSL NCT04421560 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Completed | Deep Learning Model for the Prediction of Post-LT HCC Recurrence NCT05200195 | European Hepatocellular Cancer Liver Transplant Group | — |
| Completed | Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to NCT03941262 | NKGen Biotech, Inc. | Phase 1 |
| Recruiting | ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Sol NCT03686124 | Immatics US, Inc. | Phase 1 / Phase 2 |
| Completed | TCR-engineered T Cells in Solid Tumors: IMA202-101 NCT03441100 | Immatics US, Inc. | Phase 1 |
| Completed | Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling NCT03760952 | Immatics US, Inc. | — |
| Completed | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors NCT03758781 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | Postoperative Complication After Free Flap Reconstruction for Head and Neck Cancer NCT04326088 | Chang Gung Memorial Hospital | — |
| Completed | Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck NCT03132038 | UNICANCER | Phase 2 |
| Unknown | SBRT for Extra-cranial Oligorecurrent Tumor NCT02410187 | Korea Cancer Center Hospital | Phase 2 |